Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time
Beijing and Bridgewater, New Jersey, December 6, 2021/PRNewswire/ - Gan Li Pharmaceutical Co., Ltd. (hereinafter referred to as Gan Li, stock code: 603087.SH), is pleased to announce that American Foods and The Drug Administration (FDA) has approved an investigational new drug (IND) application for the company's compound GZR18 to improve the management of type 2 diabetes. The research compound GZR18 is a new analogue of glucagon-like peptide-1 (GLP-1), which is an incretin hormone responsible for many glucose-regulating effects, such as stimulating insulin secretion and inhibiting hyperglycemia when blood sugar is high White. 1
Currently, 537 million adults (20-79 years old) worldwide suffer from diabetes2, and type 2 diabetes accounts for approximately 90% of all diabetes cases. 3 Gan & Lee understands the global burden of type 2 diabetes. "The FDA's approval of GZR18's IND application is an important milestone for our company as we strive to provide additional treatment options for patients with type 2 diabetes worldwide," Dr. Kaushik Dave RPh., MBA, Vice President of Global Regulatory Talk about affairs. The FDA's IND acceptance will allow Gan & Lee to conduct GZR18 phase 1 clinical trials.
About Ganli Ganli Pharmaceutical has developed China's first biosynthetic human insulin. At present, we have five recombinant insulin analogues commercialized in China, including long-acting Ganjing injection (Basalin®), quick-acting lispro injection (Prandilin™), quick-acting aspartic injection (Rapilin®), and mixed fish essence Protein zinc lispro injection (25R) (Prandilin™25), aspartic acid 30 injection (Rapilin®30) and a kind of human insulin injection-mixed protamine human insulin injection (30R) (Similin®30) ). We have two approved medical devices in China, reusable insulin injection pens (GanleePen) and disposable pen needles (GanleeFine®).
In the future, Gan Li will strive to achieve comprehensive coverage in the field of diabetes diagnosis and treatment. To advance our goal of becoming a world-class pharmaceutical company, we will also actively participate in the development of new chemical entities and work on the treatment of cardiovascular diseases, metabolic diseases, cancer and other therapies. For more information, please contact us at [email protected].
Gina Antonucci, #: 888-288-5395, [Email protection]
Source: Gan Li Pharmaceutical Co., Ltd.
More news releases on similar topics
Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time